Non Invasive Prenatal Testing Market

The global non-invasive prenatal testing (NIPT) market is projected to reach USD 14.1 billion by 2029 from USD 7.2 billion in 2024 at a CAGR of 14.5%.

The Non-Invasive Prenatal Testing (NIPT) market provides products and services to diagnose chromosomal abnormalities like Down syndrome, Patau syndrome, and microdeletion syndrome in fetuses using cell-free DNA from maternal blood. This market includes consumables such as assay kits, reagents, and disposables, as well as instruments like ultrasound devices, next-generation sequencing (NGS) systems, polymerase chain reaction (PCR) instruments, and microarrays. NIPT diagnostic tests offer a complete range of solutions for early and accurate detection of these genetic conditions, ensuring better prenatal care and informed decision-making for expectant parents.

To know about the assumptions considered for the study download the pdf brochure

The prominent players of global Non-Invasive Prenatal Testing (NIPT) market are Illumina, Inc. (US), Natera, Inc. (US), Laboratory Corporation of America Holdings (US), Eurofins Sceintific (France), F. Hoffmann-La Roche AG (Switzerland), Revvity, Inc. (US), Thermo Fisher Scientific Inc (US), Agilent Technologies (US), GE Healthcare Technologies Inc. (US), Quest Diagnostics Incorporated (US), Sonic Healthcare Limited (Australia), Centogene N.V. (Germany), Qiagen N.V. (Germany), Pathwest Laboratory Medicine WA (Australia), Myriad Genetics Inc. (US), BGI Genomics Co., Ltd. (China), Oxford Nanopore Technologies Plc. (UK), Medgenome (India), Neuberg Diagnostics (India), Annoroad Gene Technology (China), Next Biosciences (South Africa), Lilac Insights (India), Invitae Corporation (US), Baylor Genetics (US), and Raven (US). These companies adopted strategies such as product launches, partnerships, acquisitions, and expansions to strengthen their presence in the endoscopy equipment market.

Illumina, Inc. (US)

Illumina, Inc. is a molecular diagnostics company specializing in developing, manufacturing, and marketing integrated systems for genetic variation and biological function analysis. Their product range includes integrated systems, consumables, and analysis tools that simplify genetic analysis. Illumina's non-invasive prenatal testing products and services are provided through its core Illyming business segment. Additionally, Illumina offers software and informatics platforms, including cloud-based tools for sequencing and array-based systems. The company serves genomic research centers, government labs, academic institutions, pharmaceutical and biotech companies, and hospitals. Illumina operates globally in North America, Europe, Latin America, the Middle East, Africa, and the Asia Pacific. Its key subsidiaries include BlueGnome, Epic Sciences, Verinata Health, Edico Genome, Helix Holdings, Enancio, and Emedgene Technologies. In 2024, Illumina launched DRAGEN v4.3, an advanced software for next-generation sequencing data analysis, and in 2023, opened a new office and Illumina Solutions Center in Bengaluru, India, to strengthen its presence in the APAC region.

Thermo Fisher Scientific, Inc. (US)

Thermo Fisher Scientific, Inc. creates, produces, sells, and distributes analytical tools, reagents, consumables, equipment, and software. Their products serve the pharmaceutical, biotechnology, hospital, clinical lab, university, research, government, and environmental sectors. The company operates in four segments: Laboratory Products and Services, Life Sciences Solutions, Specialty Diagnostics, and Analytical Instruments. The Life Sciences Solutions and Specialty Diagnostics segments provide sequencing reagents, assays, kits, PCR instruments, consumables, software, and services. Thermo Fisher operates under five main brands: Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services, and is having presence in over 150 countries in North America, Europe, Asia, and Latin America. Some subsidiaries include Thermo Fisher Scientific Peru S.A., Laboratory Management Systems, Inc., Open BigSystems, Inc., Lomb Scientific Pty Limited, and Thermo Fisher Scientific C.V. In 2023, Thermo Fisher partnered with Pfizer Inc. to expand next-generation sequencing testing in over 30 countries in Latin America, Africa, the Middle East, and Asia.

F. Hoffmann-LA Roche AG (Switzerland)

F. Hoffmann-LA Roche AG is a global pharmaceutical company that develops, produces, distributes, and markets diagnostic and therapeutic products. It operates two main divisions: Pharmaceuticals and Diagnostics. The Diagnostics division's molecular subsegment offers PCR (including qPCR and PCR) products and services, while the sequencing unit provides genome sequencers, reagents, consumables, tests, and services for hospitals, genetic research institutes, and clinical labs. Roche operates in over 100 countries, including the US, Australia, China, and Germany, with 29 manufacturing sites worldwide, including 19 for pharmaceuticals, 8 for diagnostics, and 2 joint sites. Roche distributes products in 180 countries and owns notable subsidiaries like Chugai Pharmaceutical in Japan and Foundation Medicine in the US. In 2021, Roche launched the AVENIO Edge System to automate next-generation sequencing sample prep and acquired TIB Molbiol to develop rapid assays for emerging pathogens and health threats.

Related Reports:

Non-invasive Prenatal Testing (NIPT) Market by Product & Service (Consumables (Assay Kits & Reagents), Instruments (NGS Systems, Microarrays)), Method (Biochemical Screening, Cell-free DNA Test), End User (Diagnostic Labs) - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]